Global Expansion Potential Sanovel aims to become a global pharmaceutical company with EU GMP and FDA approvals, indicating readiness for international partnerships, licensing, and co-development opportunities in markets seeking Turkish-manufactured or Latin product lines.

Robust R&D & IP Strong emphasis on R&D, patents, and intellectual property positions Sanovel to partner on new formulations, generic equivalents, or specialty therapies, leveraging their production capacity and innovation leadership to accelerate time-to-market.

Large Manufacturing Capacity With an annual production capacity of 227 million units and a major Silivri campus, Sanovel can support high-volume contract manufacturing, private-label arrangements, and expansion of existing product lines to meet rising demand in multiple regions.

Strategic Licensing Link Existing licensing collaboration with PharmaMar for Yondelis in Turkey demonstrates openness to strategic partnerships in oncology, suggesting alignment for additional licensed or co-developed oncology or marine-derived compounds.

Sustainability & Talent A sustainability-driven mission and a large workforce (over 1,700 employees) create a compelling narrative for ESG-aligned partnerships, employee-focused program selling points, and joint ventures that emphasize long-term value and local economic impact.